Preeclampsia Market
Industry
- Automobile and Transportation
- Chemicals and Materials
- Consumer Goods
- Energy and Power
- Electronics and Semiconductor
- Food and Beverages
- Machinery and Equipment
- Pharma and Healthcare
- Service and Software
- Others
- Packaging
- ICT
- Technology
- Medical Devices and Consumables
- Agriculture
- Medical Care
- Aerospace and Defense
Preeclampsia Market Size, Share & Analysis By Product (Instrument, Consumables), By Test Type (Blood Tests, Urine Tests), By End-Use (Hospitals, Clinics, Diagnostic Centers, Others), By Region (North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa), and Growth Forecast To 2032
Report ID: RV22638 | Published: Jan 2023 | Historical Period: 2018-2021 | Pages: 200 | Price: $3260| Industry: Pharma and Healthcare
Preeclampsia Market Overview 2023:
The Global Preeclampsia Market is expected to register a rapid revenue of 4.5% CAGR over the forecast period. Key factors such as increasing incidence of preeclampsia, rapid advancements in diagnostic technologies, and rising focus on product launches are expected to drive global market growth during the forecast period.
Preeclampsia, also known as toxemia is a complication in pregnancy characterized by high blood pressure, high levels of protein in urine, and damage to organs like the liver and kidneys. It usually begins after 20 weeks gestation and can be fatal for both mother and fetus if left untreated. Some common symptoms include proteinuria, thrombocytopenia, severe headaches, change in vision, shortness of breath, pain in the upper belly, and nausea.
The most common and effective treatment option for toxemia is immediate delivery of the infant. However, in critical situations where immediate delivery is not possible, medications such as corticosteroids, anticonvulsant medications, and antihypertensive drugs or best rest is advised.
Factors such as increasing healthcare expenditure, rising efforts by government and healthcare institutes to improve maternal and fetal healthcare, increasing investments in R&D activities for accurate diagnosis, and global initiatives to lower the disease burden are expected to drive global market growth during the forecast period. Moreover, collaborations among research institutions, diagnostic companies, and healthcare providers is expected to open doors for innovations and better product outcomes. This is also expected to boost overall market growth going ahead.
However, the costs associated with the research and development of new therapies is high as it requires extensive clinical trials and regulatory approvals.
Graphical Overview:
Key Takeaways:
Rising Maternal Age:
Over the years, changing lifestyle patterns and advances in medical treatments have resulted in advanced maternal age. This also increases the risks of preeclampsia. However, people are steadily becoming aware of the importance of early diagnosis and treatment for the disease. This is a key factor expected to drive global market growth during the forecast period.
High Risk of Adverse Events and Limited Treatment Options:
Developing tools and medications that are safe for the mother as well as the fetus can be challenging. Thus, rising risks of potential adverse events can affect the development and adoption of new therapies. In addition, limited availability of effective treatments for preeclampsia and low awareness about this condition especially in developing economies can impact the overall market growth during the forecast period.
Market Opportunities:
Though preeclampsia diagnosis and treatments are widely used across healthcare sectors, developing tools for precise biomarker identification and imaging techniques can be a significant opportunity for existing market players and new entrants. In addition, market players can focus on developing advanced tools and diagnostic solutions due to rising inclination towards remote monitoring and telehealth and low awareness about preeclampsia in many developing economies.
Product Outlook:
Based on product type, the global market is segmented into instruments and consumables. The consumables segment is expected to register rapid revenue CAGR over the forecast period owing to high demand for various types of consumables and reagents for diagnostic testing, and ongoing research and clinical studies on improving the diagnosis and treatment of preeclampsia.
Test Type Outlook:
Based on test type, the blood tests segment is expected to account for a significantly larger revenue share during the forecast period. This growth can be driven by factors like growing prevalence of preeclampsia across the globe, rapid advancements in preeclampsia tests and diagnostic tools, and high preference for blood tests to check for low platelet counts, asses liver health, kidney functionality, and abnormalities in the blood clotting system.
End Use Outlook:
The global market is segmented into hospitals, clinics, diagnostic centers, and others based on end use. Among these, the hospitals segment is expected to account for largest revenue share during the forecast period attributed to rising hospital admissions for preeclampsia, improving healthcare infrastructure and facilities, and rising availability of advanced preeclampsia diagnostic tools and kits.
Regional Outlook:
North America is expected to account for largest revenue share during the forecast period owing to increasing incidence of preeclampsia across the region, rising awareness about early diagnosis and treatment, presence of well-developed healthcare infrastructure and facilities, and rapid advancements in diagnostic technologies. In addition, presence of leading companies, high healthcare expenditure, and rising investments in developing more effective, advanced preeclampsia diagnostic kits are other factors expected to drive North America market growth during the forecast period.
Asia Pacific market is expected to register rapid revenue CAGR over the forecast period attributed to rapid adoption of advanced diagnostic tools, growing awareness about preeclampsia among healthcare providers and patients, rising healthcare spending, and high focus on improving healthcare infrastructure and diagnostics. Moreover, rapid urbanization, rising individual spending and efforts by diagnostic companies to expand their presence in this region are other factors expected to drive Asia Pacific market growth going ahead.
Report Coverage:
| Report Details | Outcome |
| Base Year for Estimation | 2022 |
| Historical Data | 2018-2021 |
| Forecast Period | 2023-2032 |
| Segments Covered: | Product, Test Type and Regional |
| By Product | Instrument, Consumables |
| By Test Type | Blood Tests, Urine Tests |
| By End Use | Hospitals, Clinics, Diagnostic Centers, Others |
| Regional Scope | North America, Europe, Asia Pacific, Latin America, Middle East and Africa |
| Country Scope | United States, Canada, Germany, France, UK, Italy, Russia, China, Japan, South Korea, Southeast Asia, India, Mexico, Brazil, Saudi Arabia, UAE, Turkey |
| Qualitative Info | •Value Chain Analysis •Pricing Analysis •Regional Outlook •Market Trends •Market Share Analysis •Competition Analysis •Technological Advancements |
| Key Players | Diabetomics, Inc., Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd, PerkinElmer Inc., Siemens Healthineers AG, DRG INSTRUMENTS GMBH, Metabolomic Diagnostics Ltd., Sera Prognostics, MOMM Diagnostics, Miraculins Inc. |
| Customization Scope | 10 Hours of Free Customization and Expert Consultation |
Competitive Landscape:
The global Preeclampsia market is extremely competitive, comprising several regional and global level key players. Leading key players are focused on adopting various strategic alliances like mergers and acquisitions, partnerships, joint ventures, collaborations, and product launches to maintain their global position and enhance their product offerings. They are also focused on innovation, and scalability, and are adapting to evolving technology trends and consumer needs.
Some Leading Market Companies Listed in the Report:
- Diabetomics, Inc.
- Thermo Fisher Scientific Inc.
- Hoffmann-La Roche Ltd
- PerkinElmer Inc.
- Siemens Healthineers AG
- DRG INSTRUMENTS GMBH
- Metabolomic Diagnostics Ltd.
- Sera Prognostics
- MOMM Diagnostics
- Miraculins Inc.
Preeclampsia Industry Recent Developments:
- In May 2023, Thermo Fisher received FDA approval for its immunoassay for risk evaluation and clinical management of preeclampsia.
- In February 2022, Momm Diagnostics a Switzerland-based startup announced the launch of a point-of-care preeclampsia test by 2024
- In July 2020, PerkinElmer, Inc. announced the addition of the DELFIA Xpress sFlt-1 kit to its CE-IVD preeclampsia product offerings.
The global Preeclampsia Market has been segmented based on Product, Test Types, End-use, and Region:
By Product:
- Instruments
- Consumables
By Test Types:
- Blood Tests
- Urine Tests
By End Use:
- Hospitals
- Clinics
- Diagnostic Centers
- Others
By Region:
- North America
- United States
- Canada
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Nordic Countries
- Asia Pacific
- China
- Japan
- South Korea
- Southeast Asia
- India
- Australia
- Rest of Asia
- Latin America
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
- Rest of MEA
Frequently Asked Questions!
- Diabetomics, Inc.
- Thermo Fisher Scientific Inc.
- Hoffmann-La Roche Ltd
- PerkinElmer Inc.
- Siemens Healthineers AG
- DRG INSTRUMENTS GMBH
- Metabolomic Diagnostics Ltd.
- Sera Prognostics
- MOMM Diagnostics
- Miraculins Inc.
To Learn More About This Report
Our Clients
